234 results on '"Mishima, A."'
Search Results
2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
3. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
4. PS4-1 Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
5. O4-5 Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan
6. O13-3 Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
7. P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy
8. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
9. GL1-1 Clinical Practice Guideline for tumor-agnostic treatment in patients with advanced solid tumors focus on DNA mismatch repair and tumor mutation burden
10. O12-1 Ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma: RAM-NEC study (WJOG13420G)
11. MO42-6 The clinical and molecular landscape of focal MET-amplified metastatic colorectal cancer patients
12. 599TiP PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
13. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression
14. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study
15. MO42-6 The clinical and molecular landscape of focal MET-amplified metastatic colorectal cancer patients
16. O1-15-1 - Azacytidine is effective in the therapy related myelodysplastic syndrome
17. O1-6-1 - Tolerability and pharmacokinetics (PK) of ABT-414 in Japanese patients (pts) with malignant glioma
18. MO25-3 Safety and pharmacokinetics of tusamitamab ravtansine dosing Q3W in Japanese patients with advanced solid tumors.
19. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy
20. O12-1 Ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma: RAM-NEC study (WJOG13420G)
21. GL1-1 Clinical Practice Guideline for tumor-agnostic treatment in patients with advanced solid tumors focus on DNA mismatch repair and tumor mutation burden
22. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
23. P-276 Safety and Efficacy of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naïve Metastatic Colorectal Cancer (SAPPHIRE)
24. P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)
25. 1005P A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity
26. LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial
27. 987P A new therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
28. O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
29. MO20-3 Real-world outcomes of surgery versus chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
30. GL-1 Clinical recommendations on the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair (dMMR) tumors
31. GL-2 Clinical recommendations on the diagnosis and use of TRK inhibitors in adult and pediatric patients with NTRK fusion-positive advanced solid tumors
32. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
33. LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial
34. O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
35. PHASE II STUDY OF S-1 PLUS LEUCOVORIN (NEW 1 WEEK TREATMENT REGIMEN FOLLOWED BY 1 WEEK REST PERIOD) IN PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER IN JAPAN AND CHINA
36. NUMBER OF INVOLVED ORGANS IS PREDICTIVE FACTOR OF RESPONSE TO CYVADIC CHEMOTHERAPY FOR ADVANCED SOFT TISSUE SARCOMA PATIENTS
37. TPF INDUCTION CHEMOTHERAPY FOLLOWED BY CISPLATIN-BASED CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE IV HEAD AND NECK CANCER DEMONSTRATED NO BENEFIT
38. 460P Update analysis of phase II study of oxaliplatin based regimen in relapsed colorectal cancer patients treated with oxaliplatin based adjuvant chemotherapy: INSPIRE study
39. P-37 phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
40. P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress)
41. 1005P A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity
42. 987P A new therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
43. GL-2 Clinical recommendations on the diagnosis and use of TRK inhibitors in adult and pediatric patients with NTRK fusion-positive advanced solid tumors
44. MO20-3 Real-world outcomes of surgery versus chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
45. GL-1 Clinical recommendations on the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair (dMMR) tumors
46. P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress)
47. P2–083 - Circulating Tumor Cells as a Prognostic Marker in Metastatic Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy
48. O2–078 - Differential Treatment Strategies for Advanced Colorectal Cancer by Mutation Spectrum in the RAS-RAF Pathway and MSI
49. 460P Update analysis of phase II study of oxaliplatin based regimen in relapsed colorectal cancer patients treated with oxaliplatin based adjuvant chemotherapy: INSPIRE study
50. P-37 phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.